Integrated Quantitative Investments LLC Buys New Stake in Bioventus Inc. (NYSE:BVS)

Integrated Quantitative Investments LLC purchased a new stake in Bioventus Inc. (NYSE:BVS) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 24,925 shares of the company’s stock, valued at approximately $262,000.

Several other large investors also recently bought and sold shares of BVS. Plato Investment Management Ltd acquired a new position in shares of Bioventus in the 4th quarter valued at $38,000. Quarry LP acquired a new position in Bioventus in the third quarter valued at $59,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Bioventus in the fourth quarter valued at about $75,000. Quantbot Technologies LP purchased a new stake in Bioventus during the 4th quarter valued at approximately $103,000. Finally, Arizona State Retirement System purchased a new stake in shares of Bioventus during the fourth quarter worth approximately $109,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Bioventus Stock Down 9.0 %

Shares of NYSE BVS opened at $8.33 on Friday. The stock has a market capitalization of $682.59 million, a price-to-earnings ratio of -13.66 and a beta of 0.92. Bioventus Inc. has a 52 week low of $3.90 and a 52 week high of $14.38. The firm has a 50-day moving average price of $9.97 and a 200 day moving average price of $10.91. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

Insider Buying and Selling at Bioventus

In other Bioventus news, CFO Mark Leonard Singleton sold 5,479 shares of the firm’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $9.79, for a total transaction of $53,639.41. Following the completion of the transaction, the chief financial officer now directly owns 131,963 shares in the company, valued at approximately $1,291,917.77. This trade represents a 3.99 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Robert E. Claypoole sold 28,786 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $9.10, for a total transaction of $261,952.60. Following the transaction, the chief executive officer now directly owns 64,964 shares of the company’s stock, valued at approximately $591,172.40. This trade represents a 30.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 46,161 shares of company stock valued at $436,364. Corporate insiders own 32.90% of the company’s stock.

Wall Street Analysts Forecast Growth

BVS has been the topic of a number of analyst reports. JPMorgan Chase & Co. upgraded shares of Bioventus from an “underweight” rating to a “neutral” rating and lifted their price objective for the company from $12.00 to $13.00 in a research report on Tuesday, December 17th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 target price on shares of Bioventus in a report on Monday, March 17th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.